# US 2024/0315219 A1 · Animal model for diseases associated with absence or reduction of social dominance, and pharmaceutical composition for preventing or treating diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0315219 A1
- Document ID: US20240315219A1
- Status: Published application
- Kind: A1
- Application number: 18/577,228
- Filed: 2022-07-07
- Published: 2024-09-26
- Earliest claimed: 2021-07-07
- Assignees: Adel Inc.
- Applicants: ADEL, Inc.
- Inventors: Ji Seon PARK
- Web page: https://patentgrep.com/patent/US20240315219A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/30: for treating abuse or dependence
- C07K 14/47: from mammals
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/5088: {of vertebrates}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0356: Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
- A01K 2267/0393: Animal model comprising a reporter system for screening tests
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to an animal model in which social dominance is absent, and a pharmaceutical composition for preventing or treating diseases associated with the absence or reduction of social dominance. In an animal model, according to the present invention, social dominance is absent through inhibiting of the expression or activity of a CREB-regulated transcription coactivator 3 (CRTC3) gene or protein, and the animal model can be used as a model for diseases associated with the absence or reduction of social dominance. In addition, the present invention enables the prevention, alleviation or treatment of diseases associated with the absence or reduction of social dominance by using a composition containing agonists for brain epidermal growth factor (EGF) receptors.

## Claims

### Claim 1

An animal model lacking social dominance, in which expression or activity of CREB-regulated transcription coactivator 3 (CRTC3) gene or protein is suppressed.

### Claim 2 (depends on 1)

The animal model of claim 1, wherein the expression or activity of CRTC3 gene or protein is specifically suppressed in the brain.

### Claim 3 (depends on 1)

The animal model of claim 1, wherein the expression or activity of CRTC3 gene or protein is specifically suppressed in astrocytes of the brain.

### Claim 4 (depends on 1)

The animal model of claim 1, wherein the CRTC3 gene is knocked out or knocked down.

### Claim 5 (depends on 1)

The animal model of claim 1, wherein expression or activity of amphiregulin gene or protein is decreased in the brain as compared with a wild-type animal.

### Claim 6 (depends on 1)

The animal model of claim 1, wherein the animal model shows no changes in memory-related behavior, sensory-related behavior, or both as compared with a wild-type animal.

### Claim 7 (depends on 1)

The animal model of claim 1, wherein the animal model has decreased functional connectivity between prefrontal cortex and parietal cortex in the brain as compared with a wild-type animal.

### Claim 8 (depends on 1)

The animal model of claim 1, wherein the animal model is a model for a disease related to lack or reduction of social dominance.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the disease is a disease accompanied by or caused by social defeat stress.

### Claim 10 (depends on 8)

The animal model of claim 8, wherein the disease is at least one selected from the group consisting of chronic inflammation, self-harming, suicidal ideation, anti-social personality disorder, aggressive personality, chronic stress, anxiety neurosis, drug intoxication or mental or behavioral disorder caused by drug intoxication, schizophrenia, mood disorder, mania, depressive disorder, bipolar disorder, fragile X syndrome, autism spectrum disorder, and autism.

### Claim 11 (depends on 1)

The animal model of claim 1, wherein the animal is selected from the group consisting of mouse, hamster, rat, guinea pig, monkey, dog, cat, rabbit, cow, sheep, pig, and goat.

### Claim 12

A method of producing an animal model lacking social dominance, comprising suppressing expression or activity of CREB-regulated transcription coactivator 3 (CRTC3) gene or protein.

### Claim 13 (depends on 12)

The method of claim 12, wherein the suppressing comprises knocking out or knocking down the CRTC3 gene.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method for screening a therapeutic agent for a psychiatric disease, comprising administering a candidate drug for treatment of a psychiatric disease to the animal model lacking social dominance of any one of claims 1 to 11; and determining whether social dominance of the animal model is improved.

### Claim 15 (depends on 14)

The method of claim 14, wherein the psychiatric disease is accompanied by symptoms of lack or reduction of social dominance.

### Claim 16 (depends on 14)

The method of claim 14, wherein the determining is performed by a behavioral test for evaluating social dominance, electroencephalogram (EEG) analysis, brain MRI analysis, measurement of expression or activity level of amphiregulin in a biological sample derived from the animal model, or a combination thereof.

### Claim 17

A pharmaceutical composition for preventing or treating a disease related to lack or reduction of social dominance, comprising as an active ingredient an agonist for epidermal growth factor (EGF) receptor in the brain.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the agonist for EGF receptor comprises amphiregulin, a fragment thereof, or a nucleic acid encoding the same.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the amphiregulin or the fragment thereof comprises EGF domain of amphiregulin.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, wherein the amphiregulin comprises the amino acid sequence represented by SEQ ID NO: 8.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19, wherein the EGF domain of amphiregulin comprises the amino acid sequence represented by SEQ ID NO: 10.

### Claim 22 (depends on 17)

The pharmaceutical composition of claim 17, wherein the disease is caused by impaired expression or decreased activity of CREB-regulated transcription coactivator 3 (CRTC3).

### Claim 23 (depends on 17)

The pharmaceutical composition of claim 17, wherein the disease is accompanied by or caused by social defeat stress.

### Claim 24 (depends on 17)

The pharmaceutical composition of claim 17, wherein the disease is at least one selected from the group consisting of chronic inflammation, self-harming, suicidal ideation, anti-social personality disorder, aggressive personality, chronic stress, anxiety neurosis, drug intoxication or mental or behavioral disorder caused by drug intoxication, schizophrenia, mood disorder, mania, depressive disorder, bipolar disorder, fragile X syndrome, autism spectrum disorder, and autism.

### Claim 25 (depends on 17)

The pharmaceutical composition of claim 17, wherein the composition is administered by intracerebral injection or intracerebroventricular injection (ICV).

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for preventing or treating a disease related to lack or reduction of social dominance, comprising administering to a subject the pharmaceutical composition of any one of claims 17 to 25.
